Athos Capital’s Takeda Pharmaceutical TAK Stock Holding History

Athos Capital’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-77,000	Closed	-$1.4M	–	152
2020 Q4	$1.4M	Buy	77,000 +17,000	+28%	+$298K	0.39%	45
2020 Q3	$1.07M	Hold	60,000	–	–	0.51%	42
2020 Q2	$1.08M	Buy	+60,000	New	+$1.08M	0.73%	17
2019 Q4	–	Sell	-27,163	Closed	-$467K	–	38
2019 Q3	$467K	Sell	27,163 -109,629	-80%	-$1.9M	0.46%	28
2019 Q2	$2.42M	Hold	136,792	–	–	1.07%	20
2019 Q1	$2.79M	Buy	+136,792	New	+$2.75M	1.8%	11

Other funds holding TAK

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Athos Capital's TAK Position: Q1 2021 in Review

Athos Capital sold out of Takeda Pharmaceutical (TAK) in Q1 2021, closing a stake of 77,000 shares — an estimated $1.4M sold.

Athos Capital first reported a position in TAK in Q1 2019 and held it in 6 quarters. The position peaked at $2.79M in Q1 2019. 316 funds tracked by Wall St. Rank hold TAK as of Q1 2021.

Athos Capital reported no remaining Takeda Pharmaceutical position as of Q1 2021 after selling out during the quarter.
Athos Capital sold 77,000 Takeda Pharmaceutical shares in Q1 2021, an estimated $1.4M.
Athos Capital first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 6 quarters.
Athos Capital's Takeda Pharmaceutical position peaked at $2.79M in Q1 2019.
316 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2021.

Based on Athos Capital's 13F filing for Q1 2021, filed 14 May 2021.